AstraZeneca Names Roche’s Soriot as CEO as Expirations Loom
This article is for subscribers only.
AstraZeneca Plc named Pascal Soriot, Roche Holding AG’s head of pharmaceuticals, as chief executive officer to revive sales and product development as the U.K. company faces one of the industry’s biggest patent expirations.
Soriot, 53, will join AstraZeneca on Oct. 1, the London-based company said in a statement today. He replaces David Brennan, who retired June 1 amid drug research setbacks and slower growth. Simon Lowth, who has been interim CEO, will return to his position as chief financial officer.